for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sequent Scientific Limited

SEQU.NS

Latest Trade

126.65INR

Change

2.85(+2.30%)

Volume

1,155,593

Today's Range

123.90

 - 

129.40

52 Week Range

51.70

 - 

131.50

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
123.80
Open
124.45
Volume
1,155,593
3M AVG Volume
35.13
Today's High
129.40
Today's Low
123.90
52 Week High
131.50
52 Week Low
51.70
Shares Out (MIL)
243.44
Market Cap (MIL)
29,893.97
Forward P/E
25.58
Dividend (Yield %)
0.16

Latest Developments

More

India's SeQuent Scientific March-Quarter Consol PAT Falls

CA Harbor Investments Offers To Buy Stake In India's Sequent Scientific -Offer Document

Sequent Scientific Ltd -Capacity Expansion Project At Germany Plant Put On Hold

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sequent Scientific Limited

SeQuent Scientific Limited is an India-based integrated pharmaceutical company. The Company operates in the domains of animal health and analytical services. The animal health business includes active pharmaceutical ingredient and finished dosage formulations. Its therapies targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAID), anti-infectives and dermatology. The Company’s analytical solutions business is a contract research organization specialized in analytical and bio analytical services to support the active pharmaceutical ingredient, pharmaceutical, personal care and nutraceutical companies. It provides complete analytical solutions including method validation, stability, microbiology for active pharmaceutical ingredients and finished products in a variety of dosage forms as per pharmacopoeial monographs, customer developed methods or in-house method development.

Industry

Biotechnology & Drugs

Contact Info

120 A & B, Industrial area, Baikampady

560078

India

+91.80.46570338

http://www.sequent.in/

Executive Leadership

Manish Gupta

Chief Executive Officer, Managing Director

Tushar Mistry

Chief Financial Officer

Krunal Shah

Compliance Officer, Company Secretary

Gautam Kumar Das

Joint Managing Director, Executive Director

S. Devendra

Additional Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

8.5K

2019

10.4K

2020

11.8K

2021(E)

14.2K
EPS (INR)

2018

0.480

2019

1.990

2020

2.850

2021(E)

4.700
Price To Earnings (TTM)
37.90
Price To Sales (TTM)
2.47
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
20.93
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's SeQuent Scientific March-Quarter Consol PAT Falls

* MARCH-QUARTER CONSOL PAT 169 MILLION RUPEES VERSUS 171 MILLION RUPEES YEAR AGO

BRIEF-Sequent Scientific -Some Promoters Propose To Sell Entire Shareholding In Co To CA Harbor Investments

* SEQUENT SCIENTIFIC LTD -SOME PROMOTERS PROPOSE TO SELL THEIR ENTIRE SHAREHOLDING IN CO TO CA HARBOR INVESTMENTS Source text for Eikon: Further company coverage:

BRIEF-Sequent Scientific Says Carlyle Group To Buy Stake In Co

* CARLYLE GROUP ENTERS AGREEMENTS TO BUY MAJORITY STAKE IN SEQUENT SCIENTIFIC LIMITED

BRIEF-CA Harbor Investments Offers To Buy Stake In India's Sequent Scientific -Offer Document

* CA HARBOR INVESTMENTS OFFERS TO BUY UP TO 64.6 MILLION SHARES OF INDIA'S SEQUENT SCIENTIFIC- OFFER DOCUMENT

BRIEF-Sequent Scientific Ltd -Capacity Expansion Project At Germany Plant Put On Hold

* SEQUENT SCIENTIFIC LTD -FACTORY OPERATIONS ACROSS LOCATIONS WORLDWIDE ARE WORKING WITH REDUCED STAFF

BRIEF-India's SeQuent Scientific Gets WHO-Geneva Approval For Its Vizag Facility

* GOT WHO-GENEVA APPROVAL FOR API PRAZIQUANTEL UNDER PRE-QUALIFICATION PROGRAM Source text for Eikon: Further company coverage:

BRIEF-India's Sequent Scientific March-Qtr Consol Profit Rises

* MARCH QUARTER CONSOL NET PROFIT 4 BILLION RUPEES VERSUS PROFIT OF 68.2 MILLION RUPEES YEAR AGO

BRIEF-India's Sequent Scientific Dec Qtr Consol Loss Narrows

* DEC QUARTER CONSOL LOSS 84.8 MILLION RUPEES VERSUS LOSS 105.8 MILLION RUPEES YEAR AGO

BRIEF-Sequent Scientific Gets Shareholders' Nod For Scheme Of Arrangement with Strides Shasun

* GETS SHAREHOLDERS' NOD TO APPROVE SCHEME OF ARRANGEMENT BETWEEN STRIDES SHASUN, CO AND SOLARA ACTIVE PHARMA SCIENCES Source text: (http://bit.ly/2DoTPO4) Further company coverage:

BRIEF-India's Sequent Scientific posts Sept-qtr profit

* Sept quarter profit 305.4 million rupees versus loss 44.5 million rupees year ago

BRIEF-Sequent Scientific seeks shareholders' nod for appointment of Sharat Narasapur as joint MD

* Seeks shareholders' nod for appointment of Sharat Narasapur as joint managing director Source text - http://bit.ly/2eHgk78 Further company coverage:

BRIEF-India's Sequent Scientific posts June-qtr consol profit

* June quarter consol profit 22.5 million rupees versus loss 118.7 million rupees year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up